pDC Reprogramming Composition Using Transcription Factor Combinations
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for generating homogeneous populations of functional plasmacytoid dendritic cells (pDCs) are limited by the low number of these cells in circulation and the inefficiency of using autologous DC precursors or hematopoietic progenitors, particularly in cancer patients, necessitating alternative strategies for generating pDCs to induce effective antiviral and anti-tumoral responses.
Innovation Solution
The use of specific combinations of isolated transcription factors, such as IRF8 and SPIB, along with other factors like BCL11A, CBFA2T3, CREB3L2, ETS1, STAT1, TCF4, TCF12, or TSC22D1, to reprogram pluripotent or differentiated cells into pDCs or interferon type I-producing cells, capable of secreting type I interferons and responding to TLR7 and TLR9 ligands.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If autologous DC precursors or hematopoietic progenitors are used to generate pDCs, then the process is simple and direct, but the efficiency is low particularly in cancer patients
Solution Approach 1:
The patent introduces transcription factors (IRF8, SPIB, and other hematopoietic transcription factors) as intermediary molecules that mediate the conversion of readily available cells (fibroblasts, peripheral blood mononuclear cells) into functional pDCs. These transcription factors act as mediators that reprogram the cellular identity, bypassing the limitations of using scarce autologous DC precursors while maintaining high efficiency in generating homogeneous pDC populations.
2Manufacturing precision
If transcription factor combinations are used to reprogram cells into pDCs, then homogeneous and functional pDC populations are generated, but the process complexity increases
Solution Approach 1:
The patent employs specific combinations of transcription factors (IRF8, SPIB, and additional factors like BCL11A, CBFA2T3, CREB3L2, ETS1, STAT1, TCF4, TCF12, or TSC22D1) to precisely control the reprogramming process. By changing the molecular parameters (transcription factor composition and ratios), the method achieves high manufacturing precision in generating homogeneous pDC populations with consistent functional characteristics, including type I interferon production capability.
3Ease of operation
If conventional methods are used to obtain pDCs, then the procedure is straightforward, but the number of cells available is insufficient for effective therapy
Solution Approach 1:
The patent makes the reprogramming method universally applicable to multiple cell types including fibroblasts, peripheral blood mononuclear cells, and other readily available cells. This multi-functional approach allows the same transcription factor combination strategy to work across different starting cell types, dramatically expanding the quantity of pDCs that can be generated from abundant cell sources rather than relying on scarce circulating DC precursors.
Data Source
AI summary
The present disclosure relates to compositions, constructs and vectors for reprogramming cells into plasmacytoid dendritic cells or interferon type I-producing cells, methods and uses thereof. The present disclosure relates to the development of methods for making plasmacytoid dendritic cells or interferon type I-producing cells that promote antiviral and anti-tumoral immune responses from differentiated, multipotent or pluripotent stem cells by introducing and expressing isolated/synthetic transcription factors. More particularly, the disclosure provides methods for obtain plasmacytoid dendritic cells or interferon type I-producing cells by direct cellular reprogramming with the surprisingly use of combinations of specific transcription factors.